AGT and heart failure: Navitoclax also decreased cardiac fibrosis, hypertrophy, inflammation, and cardiac dysfunction in mice with doxorubicin-induced heart failure, a chemotherapy-induced cardiomyopathy mouse model [260,261], and in mice with Ang II-induced heart failure, which is a model for heart failure in elderly people [262].